Sorafenib CAS 284461-73-0 Puritas ≥99.0% (HPLC) API Factory Quality
Commercial Supple Sorafenib Tosylate et intermedia:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolamide CAS:
4-Chloro-3-(Trifluoromethyl) phenyl Isocyanate CAS: 327-78-6
| Nomen | Sorafenib |
| Synonyma | Sorafenib Free Base |
| CAS Number | 284461-73-0 |
| CATTUS Number | RF-API04 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C21H16ClF3N4O3 |
| M. Pondus | 464.82 |
| Density | 1.454±0.06 g/cm3 |
| Solubilitas | Solutum in DMSO |
| Shipping Conditions | Ambientium, temperatus |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad Off-White pulveris |
| Puritas / Analysis Methodus | ≥99.0% (HPLC) |
| Lepidium sativum | H-NMR, MS |
| Damnum in Siccatio | ≤1.0% |
| Residere in Ignition | ≤0.10% |
| una immunditia | ≤0.20% (HPLC) |
| Totalis immunditias | ≤1.0% (HPLC) |
| Metalla gravis | ≤20ppm |
| Solutio in claritate | Conformare ad Latin |
| Test Standard | Enterprise Standard |
| Consuetudinem | RCC & HCC |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Sorafenib Tosylate (CAS: 475207-59-1) est novum genus pharmaci antitumoris multi-scopi, a Germanico Bayer pharmaceutico enucleatum, et in experimentis animali preclinicis antitumorem expansivum ostendit.Sorafenib praesto est in tabulis CC-mg pro administratione oralis adhibenda in curatione RCC et HCC.Sorafenib Tosylate (CAS: 475207-59-1) simul afficit cellas tumoris et vasa sanguinis tumorem.Habet duplicem antitumorem effectum: cellam signo transductionis meatus mediante RAF/MEK/ERK obstruere potest ut directe inhibeat tumorem cellularum incrementorum, dum etiam inhibet VEGF et laminae incrementi derivatorum (PDGF) receptores ad impediendum sanguinis tumorem novum formandum. vasis fictilibus, obliquo tumore cellulae incremento inhibito.Sorafenib inhibitor est Raf-I et B-RAF ac plurium kinasium tyrosinorum.
